For over thirty years, treating pattern baldness meant either altering systemic hormones throughout the entire body with oral finasteride or relying on nonspecific vascular stimulants like minoxidil. The results demonstrated that selectively blocking androgen receptors directly inside the hair follicle achieved up to a 5.39-fold (539%) relative improvement in target-area hair regrowth compared to vehicle, with no systemic hormonal disruption or sexual side effects.
What Is It and How Does It Work?
The breakthrough centers on Direct Follicular Androgen Receptor Antagonism via Clascoterone (CB-03-01)—a targeted topical anti-androgen that neutralizes dihydrotestosterone (DHT) locally without entering systemic circulation in active amounts.
-
The Systemic DHT Problem: Traditional 5-alpha reductase inhibitors like finasteride and dutasteride work by suppressing DHT production throughout the entire bloodstream and body, which carries risks of hormonal side effects, mood changes, and sexual dysfunction.
-
Local Receptor Competitive Inhibition: Clascoterone is a synthetic steroidal molecule applied directly to the scalp. It directly competes with circulating DHT for the androgen receptor binding sites inside the follicle dermal papilla cells.
-
Rapid Breakdown Prevents Systemic Exposure: Once clascoterone penetrates the scalp skin to protect the hair root, trace amounts that absorb into the bloodstream are rapidly hydrolyzed into inactive cortexolone, eliminating body-wide anti-androgenic effects.
The Science: Clear Results from the 1,465-Patient Phase 3 Program
The two identically designed, randomized, double-blind, vehicle-controlled trials evaluated twice-daily application of clascoterone 5% solution across 51 medical centers in the United States and Europe:
-
Up to 539% Relative Hair Regrowth Over Vehicle: In the SCALP 1 trial, patients applying clascoterone 5% solution achieved a 5.39-fold (539%) relative increase in Target Area Hair Count (TAHC) compared to vehicle (p < 0.05). In the parallel SCALP 2 trial, treated patients achieved a 1.68-fold (168%) relative improvement over vehicle.
-
Statistically Significant Patient-Reported Satisfaction: Combined analysis across both studies confirmed significant improvements in Patient-Reported Outcomes (PROs), confirming that patients noticed visible aesthetic thickening and density gains in the mirror.
-
Side Effect Profile Identical to Placebo: Treatment-emergent adverse events were equivalent between clascoterone and the vehicle group (mostly mild, transient dryness or redness), with zero systemic anti-androgenic complications, gynecomastia, or sexual adverse events recorded across 1,465 participants.
“For decades, patients have had to choose between available treatment options with limited efficacy or safety issues due to systemic hormonal exposure. These findings show the potential for clascoterone 5% topical solution to change that equation by delivering real, measurable regrowth with negligible systemic exposure.”— Dr. Maria Hordinsky, Professor of Dermatology at the University of Minnesota and Lead Investigator.
When Will It Be Available?
-
Current Stage: Completed 12-month Phase 3 safety extension studies and pivotal clinical trials (NCT05910450 and NCT05914805).
-
Timeline: Regulatory submission files are scheduled for FDA (United States) and EMA (Europe) review in early 2027, with anticipated prescription commercial availability for male pattern hair loss targeted for late 2027 to 2028.
How you can benefit from this treatment now
-
Protect Native Scalp Receptors: Because clascoterone proves that local receptor blockade halts miniaturization, you can support scalp defenses today by keeping the scalp clean of oxidized sebum and environmental DHT accumulation.
-
Leverage Safe Non-Hormonal Combinations: If you avoid oral DHT blockers due to side-effect concerns, pair topical vasodilators (like 5% minoxidil) with weekly 0.5 mm shallow microneedling to stimulate follicular blood supply while awaiting direct receptor blockers.
-
Screen for Early Miniaturization: Androgen receptor blockers work best when follicles are actively miniaturizing rather than completely scarred over; initiating evidence-based care during early Norwood stages preserves the highest follicular density.
-
Avoid Unregulated Raw Chemical Compounding: Do not purchase unverified research-grade CB-03-01 raw powder online; true clinical effectiveness relies on medical-grade penetration enhancers and stable solvent vehicles that deliver the compound into the dermal papilla without oxidizing.
Action: Check your hairline and crown for early signs of miniaturization (finer, shorter hairs) so you can intervene with approved topical therapies before follicles enter permanent dormancy.